Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

Vivek Subbiah, Tao Shen, M.T. Tetzlaff, Annikka Weissferdt, Lauren A. Byers, Tina Cascone, A. Behrang, Funda Meric‐Bernstam, Blaine H. M. Mooers, S. Michael Rothenberg, Kevin Ebata, Jie Wu